New Research Maps the Genetic Changes Behind Peritoneal Mesothelioma
- 12 hours ago
- 3 min read
Samuels M, Williams M, Hasan A, Rafie S, Saglimbeni GS, Hsia B, Nair S, Aeilias S, Tauseef A. Inactivation of BAP1 and the Hippo Pathway Characterizes the Genomic Alterations of Peritoneal Mesothelioma. Life (Basel). 2026 Feb 28;16(3):385. doi: 10.3390/life16030385. PMID: 41900904; PMCID: PMC13027819.
Peritoneal mesothelioma is a rare cancer that develops in the lining of the abdominal cavity. Because relatively few people are diagnosed with the disease, researchers still have much to learn about the genetic changes that allow it to develop and grow.
A new study published in 2026 provides a more detailed look at these changes. By identifying frequently altered genes and biological pathways, researchers hope to create a foundation for future clinical trials and more personalized treatment strategies.
The Key Study Question
Which genetic changes occur most frequently in peritoneal mesothelioma, and could these changes point researchers toward potential treatment targets?
The Big Picture
Researchers analyzed information from the American Association for Cancer Research’s Project GENIE database, which collects genomic data from cancer centers around the world.
The study included:
204 tumor samples from 192 patients with peritoneal mesothelioma
Data contributed by 19 international cancer centers
Samples examined using several forms of tumor sequencing
The researchers focused on somatic mutations—genetic changes found within the tumor itself. These are different from inherited mutations that may be passed through families.
What the Researchers Found
The most frequently altered genes were:
BAP1: approximately 26% of samples
NF2: approximately 15%
TP53: approximately 9%
SETD2: approximately 8%
Many of these genes normally help control cell growth, repair damaged DNA, or prevent abnormal cells from becoming cancerous. When these tumor-suppressor genes stop working properly, cells may grow and divide without the usual safeguards.
BAP1 was the most commonly altered gene. It plays an important role in DNA repair and in controlling how genetic information is organized and used within cells. Previous research has also connected BAP1 alterations with mesothelioma, and the new study reinforces its importance in peritoneal disease.
The researchers also identified alterations involving NF2 and other genes connected to the Hippo signaling pathway. This pathway helps regulate cell growth and prevents cells from multiplying uncontrollably. When it is disrupted, cancer cells may be able to continue growing.
Rather than finding one dominant mutation responsible for peritoneal mesothelioma, the study suggests that the disease may be driven by the combined loss of several protective systems, including:
DNA repair and chromatin-remodeling pathways
The Hippo signaling pathway
The p53 pathway, which helps stop damaged cells from dividing
Why This Matters for Patients
Understanding the genetic landscape of peritoneal mesothelioma is an important step toward developing more precise treatments.
The pathways identified in this study are already being investigated in other cancers and forms of mesothelioma. Researchers are exploring medications that affect DNA-repair processes, chromatin regulation, and the Hippo pathway. In the future, tumor sequencing may help determine which patients could benefit from certain targeted therapies or clinical trials.
However, these findings do not mean that a new treatment is currently available or that everyone with a BAP1, NF2, TP53, or SETD2 alteration should receive a particular drug. The study identified biologically promising areas for further research; it did not test treatments or show that targeting these mutations improves patient outcomes.
Important Study Limitations
The database did not include sufficient information about patients’ treatments, responses, or survival. As a result, researchers could not determine whether any particular mutation was associated with a better prognosis or response to therapy.
The tumor samples were also tested using different sequencing methods and gene panels. Information about histologic subtype—such as epithelioid, sarcomatoid, or biphasic disease—was incomplete, preventing researchers from comparing genetic patterns among those groups.
Finally, the findings have not yet been validated through laboratory experiments or prospective clinical trials.
The Bottom Line
This study offers a clearer map of the genetic changes associated with peritoneal mesothelioma. BAP1 was the most frequently altered gene, while NF2, TP53, SETD2, and several connected pathways also appeared to play important roles.
Although the findings do not change current treatment recommendations, they give researchers valuable direction for developing future therapies and designing clinical trials specifically for peritoneal mesothelioma. For patients and families affected by this rare cancer, the study represents another step toward understanding why the disease develops and how it may eventually be treated more precisely.
